Salvage surgery for chemorefractory gestational trophoblastic disease. 1994

E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.

OBJECTIVE To investigate and define better the role of salvage surgery for patients with chemorefractory gestational trophoblastic disease (GTD). METHODS A retrospective review of medical records at The University of Texas M.D. Anderson Cancer Center identified 33 patients with chemorefractory GTD who underwent salvage surgery between 1962 and 1991. The end points selected for analysis were serologic response and survival. RESULTS Initial salvage procedures consisted of 29 hysterectomies, four thoracotomies, and one nephrectomy (in conjunction with a hysterectomy). Fourteen patients (42%) had a serologic complete response (CR) to surgery (normalization of human chorionic gonadotropin [hCG]), 10 (30%) had a partial response (> 50% decrease in hCG level), and nine had no response (< or = 50% decrease in hCG level). Of 19 patients who received further chemotherapy, eight (42%) attained a CR. Four patients underwent a second salvage surgery: two thoracotomies, one craniotomy, and one partial hepatectomy. All achieved a CR. The probability of achieving a CR was influenced by the time from diagnosis to surgery, number of preoperative disease sites, preoperative World Health Organization (WHO) score, and histologic type. Survival was influenced by the type of antecedent pregnancy, number of preoperative regimens, number of preoperative disease sites, time from diagnosis to surgery, and preoperative WHO score. CONCLUSIONS Based on the findings of this study, it appears that a select subset of patients with chemorefractory GTD who have a limited number of clinically detectable tumor foci may benefit from salvage surgery.

UI MeSH Term Description Entries
D010298 Parity The number of offspring a female has borne. It is contrasted with GRAVIDITY, which refers to the number of pregnancies, regardless of outcome. Multiparity,Nulliparity,Primiparity,Parity Progression Ratio,Parity Progression Ratios,Ratio, Parity Progression,Ratios, Parity Progression
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014328 Trophoblastic Neoplasms Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691) Trophoblastic Cancer,Trophoblastic Tumor,Neoplasms, Trophoblastic,Trophoblast Cancer,Trophoblast Neoplasms,Trophoblast Tumor,Cancer, Trophoblast,Cancer, Trophoblastic,Cancers, Trophoblast,Cancers, Trophoblastic,Neoplasm, Trophoblast,Neoplasm, Trophoblastic,Neoplasms, Trophoblast,Trophoblast Cancers,Trophoblast Neoplasm,Trophoblast Tumors,Trophoblastic Cancers,Trophoblastic Neoplasm,Trophoblastic Tumors,Tumor, Trophoblast,Tumor, Trophoblastic,Tumors, Trophoblast,Tumors, Trophoblastic
D014594 Uterine Neoplasms Tumors or cancer of the UTERUS. Cancer of Uterus,Uterine Cancer,Cancer of the Uterus,Neoplasms, Uterine,Neoplasms, Uterus,Uterus Cancer,Uterus Neoplasms,Cancer, Uterine,Cancer, Uterus,Cancers, Uterine,Cancers, Uterus,Neoplasm, Uterine,Neoplasm, Uterus,Uterine Cancers,Uterine Neoplasm,Uterus Cancers,Uterus Neoplasm

Related Publications

E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
March 1995, Gynecologic oncology,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
June 2004, The Journal of reproductive medicine,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
February 1999, Zhonghua fu chan ke za zhi,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
February 2005, Zhonghua fu chan ke za zhi,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
November 1994, Gynecologic oncology,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
July 2004, Der Pathologe,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
June 2004, The Journal of reproductive medicine,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
July 2017, Gynecologic oncology,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
June 2010, Gynecologic oncology,
E Lehman, and D M Gershenson, and T W Burke, and C Levenback, and E G Silva, and M Morris
January 2010, Gynecologic oncology,
Copied contents to your clipboard!